In an exclusive interview with The Fly, Cryoport (CYRX) President and CEO Jerry Shelton talked about the company, recent partnerships, growth and expansion plans, and much more. Here are some highlights:
TEMPERATURE-CONTROLLED SOLUTIONS: Cryoport is a provider of temperature-controlled solutions for the life sciences industry. "We serve the biopharma reproductive medicine and the animal health markets on a global basis, and our mission is to support life and health on Earth by providing reliable and comprehensive solutions for life sciences with our advanced technology, global supply chain network, and dedicated scientists technicians and supporting team of professionals," CEO Jerry Shelton explained to The Fly.
VINETI PARTNERSHIP: Earlier this month, Cryoport and Vineti announced a commercial partnership designed to extend the end-to-end delivery of cell and gene therapies to a growing number of patients. "This collaboration between the two companies provides a broad-based global solution," the executive noted, adding that "by pairing Vineti's supply chain orchestration platform with Cryoport's integrated temperature-controlled capabilities and near real-time monitoring, we will provide an end-to-end solution for advanced therapies supporting the assurance of improved drug product quality and patient safety."
CAUTIOUS REPORT HAS 'VERY LITTLE TRUTH TO IT': Cryoport was recently mentioned cautiously by Seeking Alpha contributor Mako Research, citing the contracts with Gilead (GILD) and Novartis (NVS) that it claimed were set to expire in 2020. Commenting on the report, Shelton said it "was a very poorly written article with very little truth to it." "The contracts that we have with these two companies - Gilead and Novartis - are evergreen contracts," he explained, adding that he expects no interruption of service.
CRYOPORT TO BENEFIT FROM SECULAR GROWTH: Some Wall Street analysts have voiced bullish views on Cryoport as they believe the company will continue to benefit from secular growth associated with the global commercialization of novel regenerative medicine therapies and related development activities by the biopharmaceutical industry. Noting that he "agrees with all of those" analysts, Cryoport's CEO said he sees a "very bright future" for the company.
BUSINESS EXPANSION: Over the long-term, the executive believes Cryoport will expand both in what the company already does and also into new markets. "Cyroport will be a much broader supply chain company as we move forward and that will be upstream and downstream," he added.
"Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. A more detailed version of this interview to follow.
For more on Cyroport’s click here.
For more on Cryoport’s partnership with Vineti click here.
For more on Cryoport’s contracts with Gilead and Novartis study click here.
For more on Cryoport’s ongoing momentum click here.
For more on Cyroport’s expansion prospects click here.
Cryoport
+0.17 (+0.96%)
Gilead
-0.39 (-0.59%)
Novartis
-0.11 (-0.13%)